Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FGF2 | P09038 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1314060 | 0.75 | BLM (0.38) | CA12CA1CA9RAB9ASMN1; SMN2 | |
| SCHEMBL1442376 | 0.69 | TSHR (0.36) | CA12CA1CA9RAB9ASMN1; SMN2 | |
| SCHEMBL20425084 | 0.67 | AKR1C3 (0.33) | CA12CA1CA9 | |
| SCHEMBL820023 | 0.65 | — | — | |
| Acrylic Acid SCHEMBL34299 | 0.65 | LMNA (0.48) | CA12CA1CA9 | |
| Acrylic Acid SCHEMBL31065455 | 0.64 | LMNA (0.40) | RAB9ASMN1; SMN2FGF2 | |
| SCHEMBL25432412 | 0.63 | BRD4 (0.33) | — | |
| SCHEMBL236431 | 0.63 | TSHR (0.56) | CA12CA9RAB9ASMN1; SMN2TSHR | |
| Bicarbonate SCHEMBL6150295 | 0.63 | CA1 (0.38) | CA12CA1CA9RAB9ASMN1; SMN2 | |
| Bicarbonate SCHEMBL14917 | 0.63 | CA1 (0.38) | CA12CA1CA9RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 778 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129438-A1 | HYDROGEL COMPOSITIONS FOR USE FOR DEPLETION OF TUMOR ASSOCIATED MACROPHAGES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-07-06 | — | — | WO | claimed |
| CN-109810198-B | Site-specific GLP-2 conjugates utilizing immunoglobulin fragments | 韩美科学株式会社 | 2023-06-06 | — | — | CN | claimed |
| US-20230090790-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2023-03-23 | — | — | US | claimed |
| CN-108136276-B | Protein complexes linked by using specific sites of immunoglobulin fragments | 韩美药品株式会社 | 2023-02-28 | — | — | CN | claimed |
| US-11571493-B2 | Co-precipitation method | NEOMEND, INC. (US) | 2023-02-07 | — | — | US | claimed |
| US-20230027238-A1 | METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX | SPECTRUM PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | claimed |
| US-11389508-B2 | Protein complex by use of a specific site of an immunoglobulin fragment for linkage | HANMI PHARM. CO., LTD. (KR) | 2022-07-19 | — | — | US | claimed |
| CN-114364393-A | Methods of treatment using G-CSF protein complexes | 光谱制药有限公司 | 2022-04-15 | — | — | CN | claimed |
| WO-2021261712-A1 | HEMOGLOBIN DERIVATIVE CO-CONJUGATED WITH FATTY ACID-LINKED PEG AND ALKOXY PEG AS A BLOOD SUBSTITUTE | SUNBIO, INC. (KR) | 2021-12-30 | — | — | WO | claimed |
| US-20210401949-A1 | Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute | SUNBIO, INC. (KR) | 2021-12-30 | — | — | US | claimed |
| EP-1601698-A4 | PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | HANMI PHARM IND CO LTD (KR) | 2006-05-03 | — | — | EP | claimed |
| CN-1761684-A | Physiologically active polypeptide conjugates with extended in vivo half-life | HANMI PHARM IND CO LTD (KR) | 2006-04-19 | — | — | CN | claimed |
| CN-1723219-A | Protein complex using immunoglobulin fragment and method for preparing the same | HANMI PHARM IND CO LTD (KR) | 2006-01-18 | — | — | CN | claimed |
| EP-1613644-A1 | PEG-PHYSIOLOGICALLY ACTIVE POLYPEPTIDE HOMODIMER COMPLEX HAVING PROLONGED IN VIVO HALF-LIFE AND PROCESS FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2006-01-11 | — | — | EP | claimed |
| EP-1601698-A1 | PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | Hanmi Pharm. Co., Ltd. (KR) | 2005-12-07 | — | — | EP | claimed |
| US-20050176108-A1 | Physiologically active polypeptide conjugate having prolonged in vivo half-life | HANMI PHARM. CO., LTD. (KR) | 2005-08-11 | — | — | US | claimed |
| WO-2005047336-A1 | PROTEIN COMPLEX USING IMMUNOGLOBULIN FRAGMENT ANDMETHOD FOR THE PREPARATION THEREOF | HANMI PHARMACEUTICAL. CO. LTD. (KR) | 2005-05-26 | — | — | WO | claimed |
| WO-2004087739-A1 | PEG-PHYSIOLOGICALLY ACTIVE POLYPEPTIDE HOMODIMER COMPLEX HAVING PROLONGED IN VIVO HALF-LIFE AND PROCESS FOR THE PREPARATION THEREOF | HANMI PHARM. CO. LTD. (KR) | 2004-10-14 | — | — | WO | claimed |
| WO-2004081053-A1 | PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | HANMI PHARM. CO. LTD. (KR) | 2004-09-23 | — | — | WO | claimed |
| US-20040180054-A1 | Physiologically active polypeptide conjugate having prolonged in vivo half-life | HANMI PHARM. CO., LTD. | 2004-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090790-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | GIPR, VIP, GLP1R | CA12 1697/4885CA1 2335/4885CA9 2268/4885 |
| US-20210401949-A1 | Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute | HBG2, HBB, HBG1 | CA12 845/4885CA1 2849/4885CA9 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.